San Diego-dependent Viking Therapeutics marked itself as a serious competitor inside the weight loss drug sector in February after revealing promising details from a mid-phase trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered for a weekly injection and in March the company unveiled